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Background: Intravitreal vascular endothelial growth factor (VEGF) inhibitors stabilize vision 
in a majority of patients with neovascular age-related macular degeneration (AMD) and can 
improve vision in almost 40% of patients. However, some individuals who respond to anti-
VEGF treatment still lose vision due to the formation of geographic atrophy (GA). While 
optical coherence tomography is often the primary imaging modality used, fluorescein 
angiography (FA) can provide useful information on GA development after choroidal 
neovascularization (CNV) regression.  
Methods: A retrospective chart review was conducted to evaluate the changes seen on FA 
over a 47-month period for 3 patients with neovascular AMD treated with anti-VEGF 
inhibitors.  
Results: All 3 patients were initially noted to have subfoveal CNV due to AMD at baseline; 
they were followed up monthly and treated on an as needed basis for at least 47 months 
with intravitreal VEGF inhibitors. All subjects had regression of their CNV lesions after VEGF 
blockade. Two subjects developed foveal atrophy.  
Conclusions: This case series depicts the changes on FA seen over a 4-year period and shows 
that GA can occur with regression of CNV after treatment with VEGF inhibitors. 
 
Introduction 
Intravitreal vascular endothelial growth factor (VEGF) inhibitors are the standard 
treatment for subfoveal choroidal neovascularization (CNV) due to age-related macular 
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monthly injections, recently it has been observed that monthly follow-up with as 
needed treatment decreased the number of injections without sacrificing the gain in 
visual acuity [3–5]. Currently, most retina specialists employ optical coherence 
tomography (OCT) to evaluate CNV lesions and determine if additional VEGF inhibition 
is needed. Although OCT has become the mainstay for retinal imaging, fluorescein 
angiography (FA) is still important in the diagnosis and monitoring of retinal 
pathologies such as CNV, especially when geographic atrophy (GA) develops after CNV 
regression [6, 7]. 
We conducted a retrospective study to evaluate the dynamic changes seen on FA in 3 
patients who had undergone serial FA imaging over 48 months of treatment with 
intravitreal (IVT) VEGF inhibitors for neovascular AMD. 
Materials and Methods 
This study was approved by the Johns Hopkins Institutional Review Board, which granted a waiver 
of consent for access to medical records for all persons included in the study. Retrospective chart 
review was performed for patients who had routine fluorescein angiograms and OCT performed as 
they were being treated with intravitreal VEGF inhibitors for neovascular AMD. Three sample cases 
are described below. 
Case Reports 
Case 1 
Patient 1 is a 75-year-old man who presented with decreased vision. Initially, his visual acuity was 
found to be 20/ 63 in the left eye with subfoveal CNV due to AMD. Baseline FA revealed a small 
subretinal hemorrhage and leakage from classic CNV (fig. 1a). One month after receiving an IVT 
injection with ranibizumab (RBZ), the CNV lesion decreased in size (fig. 1b), and it continued to 
regress and show decreasing amounts of leakage at months 3 and 6, stabilized at month 9, and 
increased in leakage at month 12 (fig. 1c–f) as the patient received additional RBZ on an as needed 
basis depending on CNV activity seen on either FA and/or OCT. At month 47 and after a total of 16 
ranibizumab injections, the CNV had completely regressed. However, GA had developed over the 
fovea resulting in a visual acuity (VA) of 20/250 (fig. 1g). 
Case 2 
Patient 2 is an 85-year-old man who presented with a VA of 20/80 in his right eye and subfoveal 
occult CNV due to AMD. On presentation, the CNV lesion was greater than 9 disc areas. One month 
after treatment with ranibizumab, the CNV had regressed and there was decreased leakage on FA. 
There was continued CNV regression through months 3, 6, 9 and 12 as the patient received additional 
RBZ on an as needed basis. At month 48 and after a total of 23 RBZ injections, there was no CNV 
leakage remaining, and the VA was 20/50, but some extrafoveal GA had developed. 
Case 3 
Patient 3 is an 80-year-old woman who presented with a VA of 20/125 and subfoveal occult CNV 
due to AMD in the left eye. At the initial visit, there was subretinal hemorrhage and leakage from CNV 
(fig. 2a). After 2 RBZ treatments, there was regression of the CNV lesion at month 2 (fig. 2b), but 
leakage returned through month 12 (fig. 2c–e). This patient was followed up for a total of 57 months, 
during which she received 20 RBZ injections and 2 bevacizumab injections. At her most recent visit, 
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Both FA and OCT images are able to monitor CNV activity after VEGF inhibition [8]. 
However, despite OCT being more commonly used today to monitor CNV lesions, FA 
and OCT have different benefits and limitations. OCT allows for visualization of the 
retina to document intraretinal or subretinal fluid and elevation of the retinal pigment 
epithelium (RPE) associated with CNV. FA visualizes the actual extent and size of the 
CNV lesion and documents leakage associated with it. Although spectral domain- (SD) 
OCT can sample a large area of the retina with high resolution, it still cannot document 
the extent of CNV seen on FA [9]. FA can truly document both the size of the CNV lesion 
and regression of it after treatment with VEGF inhibition, and aid in the diagnosis of 
geographic atrophy. More recently, ophthalmologists have also been employing SD-OCT 
for identifying areas of geographic atrophy that could be responsible for poor visual 
outcomes after anti-VEGF therapy. 
Few studies have described long-term changes in CNV lesions with FA after VEGF 
inhibition. This case series documents CNV regression induced by anti-VEGF therapy. In 
addition, it documents the development of atrophy in the macula after CNV regression. 
The GA may be due to the natural history of the disease or it may be accelerated by CNV 
regression by anti-VEGF therapy. Rosenfeld et al. [10] evaluated causes of vision loss 
after anti-VEGF therapy and also demonstrated that RPE changes and atrophy were 
common causes of vision loss after long-term use of RBZ for neovascular AMD. Their 
study evaluated 71 eyes that lost at least 15 letters of VA over a 24-month period, and 
they found that RPE atrophy and/or abnormalities were the most common causes of 
visual loss among these patients. Additional studies of OCT and FA would be helpful to 
identify if chronic anti-VEGF therapy increases the risk of GA. In addition to OCT, FA is 
still an important tool for monitoring CNV activity after VEGF inhibition and for 
documenting CNV regression and the development of atrophy in the macula. 
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Fig. 1. Late-phase fluorescein angiograms from a patient treated with ranibizumab on an as needed 
basis over 47 months. The CNV lesion measured 2 disc areas at baseline (a). After the initial 
ranibizumab treatment, the CNV lesion decreased in size at month 1 (b) month 3 (c) and month 6 (d), 
maintained this size through month 9 (e), and increased at month 12 (f). At 47 months (g), there was 




Fig. 2. Late-phase fluorescein angiograms from a patient treated with bevacizumab at baseline and 
treated with either bevacizumab or ranibizumab on an as needed basis for 57 months. The CNV 
lesion measured 1–2 disc areas at baseline (a). The lesion decreased in size slightly at month 1 (b) 
and then leaked more at month 5 (c), month 9 (d) and month 12 (e). Over 57 months, the CNV 
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